A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 08 2019
Historique:
received: 22 11 2018
accepted: 22 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 24 10 2020
Statut: epublish

Résumé

Medical oncologists are challenged to personalize medicine with scientific evidence, drug approvals, and treatment guidelines based on sequencing of clinical samples using next generation sequencer (NGS). Knowledge-based curation systems have the potential to help address this challenge. We report here the results of examining the level of evidence regarding treatment approval and clinical trials between recommendations made by Watson for Genomics (WfG), QIAGEN Clinical Insight Interpret (QCII), and Oncomine knowledge-based reporter (OKR). The tumor samples obtained from the solid cancer patients between May to June 2018 at Kindai University Hospital. The formalin-fixed paraffin-embedded tumor samples (n = 31) were sequenced using Oncomine Comprehensive Assay v3. Variants including copy number alteration and gene fusions identified by the Ion reporter software were used commonly on three curation systems. Curation process of data were provided for 25 solid cancers using three curation systems independently. Concordance and distribution of curated evidence levels of variants were analyzed. As a result of sequencing analysis, nonsynonymous mutation (n = 58), gene fusion (n = 2) or copy number variants (n = 12) were detected in 25 cases, and subsequently subjected to knowledge-based curation systems (WfG, OKR, and QCII). The number of curated information in any systems was 51/72 variants. Concordance of evidence levels was 65.3% between WfG and OKR, 56.9% between WfG and QCII, and 66.7% between OKR and QCII. WfG provided great number of clinical trials for the variants. The annotation of resistance information was also observed. Larger differences were observed in clinical trial matching which could be due to differences in the filtering process among three curation systems. This study demonstrates knowledge-based curation systems (WfG, OKR, and QCII) could be helpful tool for solid cancer treatment decision making. Difference in non-concordant evidence levels was observed between three curation systems, especially in the information of clinical trials. This point will be improved by standardized filtering procedure and enriched database of clinical trials in Japan.

Identifiants

pubmed: 31383922
doi: 10.1038/s41598-019-47673-9
pii: 10.1038/s41598-019-47673-9
pmc: PMC6683116
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11340

Références

Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Oncologist. 2018 Feb;23(2):179-185
pubmed: 29158372
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Ann Oncol. 2018 Feb 1;29(2):418-423
pubmed: 29324970
Cancer Sci. 2018 Sep;109(9):2980-2985
pubmed: 30187675
Int J Health Serv. 2014;44(4):635-42
pubmed: 25626223
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
CMAJ. 2000 Jul 25;163(2):166-9
pubmed: 10934978
J Clin Oncol. 2014 Mar 1;32(7):678-86
pubmed: 24470006
PLoS One. 2014 Jun 23;9(6):e100924
pubmed: 24956270
Hum Mutat. 2018 Nov;39(11):1614-1622
pubmed: 30311389
J Mol Diagn. 2019 Sep;21(5):884-894
pubmed: 31229654
Ann Oncol. 2015 Dec;26(12):2477-82
pubmed: 26420428
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Front Med (Lausanne). 2018 Nov 09;5:305
pubmed: 30474028
Int J Clin Oncol. 2019 Feb;24(2):123-130
pubmed: 30542800

Auteurs

Kazuko Sakai (K)

Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Masayuki Takeda (M)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Shigeki Shimizu (S)

Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Takayuki Takahama (T)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Takeshi Yoshida (T)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Satomi Watanabe (S)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Tsutomu Iwasa (T)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Kimio Yonesaka (K)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Shinichiro Suzuki (S)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Hidetoshi Hayashi (H)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Hisato Kawakami (H)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Yoshikane Nonagase (Y)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Kaoru Tanaka (K)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Junji Tsurutani (J)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Kazumasa Saigoh (K)

Department of Clinical Genetics, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Akihiko Ito (A)

Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Tetsuya Mitsudomi (T)

Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Kazuhiko Nakagawa (K)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan.

Kazuto Nishio (K)

Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, 589-8511, Japan. knishio@med.kindai.ac.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH